Error message

Warning: htmlspecialchars(): Invalid multibyte sequence in argument in check_plain() (line 1843 of /internet/sites/drupal-sanofi-pasteur-ca/includes/

30-year Industry Veteran Advocate for Advancing Science, Innovation and Canadian Competitiveness


Toronto, Ontario – April 11, 2013 – Mark Lievonen, President of Sanofi Pasteur Limited, the Canadian vaccine division of the Sanofi Group, has been inducted into the 2013 Canadian Marketing Healthcare Hall of Fame Award, in recognition of his outstanding contributions to the healthcare industry.

The Canadian Healthcare Marketing Hall of Fame was established in 1988 to honour lifetime achievement in healthcare marketing. This award is the highlight of the annual National Pharmaceutical Congress organized by the Chronicle Companies.

“Through a career spanning over 30 years, Mark Lievonen has made a lasting impact on the industry and served as a source of inspiration to others,” said Mitchell Shannon, Publisher, The Chronicle Newspapers, which sponsors the award. “The judging committee was impressed by Mr. Lievonen’s extraordinary dedication and commitment to the profession. Under his leadership, Sanofi Pasteur has become a billion dollar enterprise in Canada, and is a symbol of Canadian talent, innovation and R&D excellence.”

Lievonen is an active member in the life sciences sector. He is a member of several organizations, notably: Director, Oncolytics Biotech Inc.; Vice-Chair, Ontario Institute for Cancer Research; First Vice-Chair, Rx&D; Chair, Markham Stouffville Hospital Foundation; Director, Public Policy Forum; Governor, York University; Director, BIOTECanada; Director, Markham Stouffville Hospital; and Director, York University Development Corporation. 

“I am truly honoured to receive this recognition on behalf of Sanofi Pasteur, my colleagues and my community, and I am proud that we have been able to play a small part in preventing disease and saving lives in Canada and all around the world,” says Mark Lievonen.  “I am energized by the work we do, inspired by my passionate colleagues and humbled by our role in impacting human lives each and every day.”

Lievonen has been the recipient of the Queen’s Golden Jubilee Medallion (2002), the Chevalier de l'Ordre National de Mérite by the Government of France (2007), Fellow, Ontario Institute of Chartered Accountants (2009) and received the Queen’s Diamond Jubilee Medallion (2012). Twenty years ago, Lievonen also spearheaded Canada’s only mentored science competition, the Sanofi BioGENEius Challenge Canada (SBCC), to foster biotechnology talent in Canada among high school students.  For a complete biography click here.

Mark Lievonen joined Sanofi Pasteur Canada in 1983 and has been the President since 1999. For almost 100 years, Sanofi Pasteur has been at the forefront of innovation in vaccine R&D, and has made more than $600 million in capital expenditures since 2000.  The company manufactures over 50 million doses of vaccines in Canada for both domestic and international markets, and is the only manufacturer of 5-component acellular pertussis combination vaccines, which was launched in Canada as Pentacel® in 1997.  Sanofi Pasteur has a broad vaccine portfolio in Canada, including Pediacel®, Menactra®, Adacel®, Intanza®, Vaxigrip®, ViVaxim®, Typhim Vi® and YF-Vax®.

Nominations for the 2013 selection of honorees were solicited during the past months from the publication’s readers.  Since 1988, 95 healthcare visionaries, original thinkers and leaders have been honoured with this prestigious distinction. Numerous submissions were received and a committee consisting of the publications' editors and an ad hoc group of industry advisors undertook the difficult task of determining from among the Nominees the candidates who best exemplified the qualities described above, based on the information submitted by the individual(s) making the nomination.


About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: or


Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.




Sanofi Pasteur                                                                       CASACOM    

Nancy Simpson                                                                       Kara Latta

T. 416-667-2955                                                                     T. 416-944-2145